Breaking News, Promotions & Moves

Oxford Biomedica Appoints Dr. Frank Mathias as CEO and Board Director

Mathias previously served as CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO.

Author Image

By: Charlie Sternberg

Associate Editor

Oxford Biomedica plc, a gene and cell therapy group, has appointed Dr. Frank Mathias as chief executive officer (CEO) and board director, effective March 2023.   Mathias brings world-class innovation and contract development and manufacturing experience to Oxford Biomedica. Since 2016 he has served as CEO of Rentschler Biopharma SE, which he has successfully developed into a leading global, full-service CDMO. During the past six years, Mathias has overseen a tripling of revenues, transformed t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters